Affordable insulin Civica Rx is expanding into consumer outpatient retail with Civica insulin glargine at the lowest list price in the current long-acting insulin market, presenting a direct sales opportunity to pharmacies, retailers, and diabetes care programs seeking low-cost options.

Public sector access Recent VA Federal Supply Schedule contract and ongoing government engagement indicate opportunities to secure large-volume generic medicines for federal facilities and affiliated networks, enabling scalable B2G sales and longer-term partnerships.

Oncology generics Partnerships with Navitus to supply lower-cost generics in oncology create a potential corridor for hospital systems and managed care organizations seeking cost containment in a high-spend therapeutic area.

Trust and visibility Civica’s nonprofit, domestic manufacturing narrative and recognition as a best place to work bolster credibility with health systems and payers, supporting conversations around reliability, price stability, and supply security.

Expansion momentum From essential hospital supplies to consumer-ready affordable meds and new injections, Civica’s product expansion pipeline signals ongoing opportunity for cross-sell across hospital formularies, outpatient clinics, and community health channels.